Monte Rosa Therapeutics (NASDAQ:GLUE) reported quarterly losses of $(0.43) per share which missed the analyst consensus estimate of $(0.38) by 13.16 percent. This is a 186.67 percent decrease over losses of $(0.15) per share from the same period last year. The company reported quarterly sales of $8.968 million which beat the analyst consensus estimate of $5.524 million by 62.36 percent. This is a 61.33 percent decrease over sales of $23.194 million the same period last year.